GlassScriptPhysician profile
Cherdkiat Sangkam
NPI 1174505218
$577.17
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $104 · 2021: $27.03 · 2022: $30.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $107.39 | 2019-2020 | |
| Pfizer INC. | $100.64 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $76.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.32 | 2019-2022 | |
| Edwards Lifesciences Corporation | $48.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.44 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.33 | 2019 | |
| Chiesi USA, INC. | $21.81 | 2019 | |
| Amgen INC. | $19.43 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.55 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherdkiat Sangkam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.